Clinical Trial Update: A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated istradefylline (KW-6002) as monotherapy in Parkinson's disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• istradefylline (KW-6002) (istradefylline)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Parkinson's Disease, Movement Disorder Syndrome | Phase 2 | Status: COMPLETED